WO2005027981A1 - Mechanism-based targeted pancreatic beta cell imaging and therapy - Google Patents
Mechanism-based targeted pancreatic beta cell imaging and therapy Download PDFInfo
- Publication number
- WO2005027981A1 WO2005027981A1 PCT/US2004/030374 US2004030374W WO2005027981A1 WO 2005027981 A1 WO2005027981 A1 WO 2005027981A1 US 2004030374 W US2004030374 W US 2004030374W WO 2005027981 A1 WO2005027981 A1 WO 2005027981A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dtpa
- composition
- metal ion
- antidiabetic agent
- pancreas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Definitions
- preferred metal ions are generally those known in the art to be useful for imaging techniques including, but not limited to gamma scintigraphy, magnetic resonance, positron emission tomography, and computed tomography.
- Metal ions useful for chelation in paramagnetic Tl-Type MRI contrast agent compositions and uses may include divalent and trivalent cations orf metals selected from iron, manganese, chromium, copper, nickel, gadolinium, erbium, europium, dysprosium and holmium.
- pancreas can be imaged with radiolabeled nateglinide and glipizide.
- uptake changes in pancreas can be assessed using this specific molecular marker.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04788800A EP1675625B1 (en) | 2003-09-17 | 2004-09-16 | Mechanism-based targeted pancreatic beta cell imaging |
CA2539384A CA2539384C (en) | 2003-09-17 | 2004-09-16 | Mechanism-based targeted pancreatic beta cell imaging and therapy |
AU2004273911A AU2004273911B2 (en) | 2003-09-17 | 2004-09-16 | Mechanism-based targeted pancreatic beta cell imaging and therapy |
KR1020067005445A KR101152729B1 (en) | 2003-09-17 | 2004-09-16 | Mechanism-based targeted pancreatic beta cell imaging and therapy |
DK04788800.3T DK1675625T3 (en) | 2003-09-17 | 2004-09-16 | Mechanism-based targeted pancreatic beta-cell imaging |
CN2004800300890A CN1867363B (en) | 2003-09-17 | 2004-09-16 | Mechanism-based targeted pancreatic beta cell imaging and therapy |
ES04788800T ES2403378T3 (en) | 2003-09-17 | 2004-09-16 | Image studies of targeted pancreatic beta cells based on a mechanism |
BRPI0414512A BRPI0414512B8 (en) | 2003-09-17 | 2004-09-16 | composition to reproduce images of a pancreas and use of this |
PL04788800T PL1675625T3 (en) | 2003-09-17 | 2004-09-16 | Mechanism-based targeted pancreatic beta cell imaging |
JP2006527025A JP5395327B2 (en) | 2003-09-17 | 2004-09-16 | Mechanism-based targeted pancreatic beta cell imaging and therapy |
IL174374A IL174374A (en) | 2003-09-17 | 2006-03-16 | Use of imaging compounds for the preparation of compositions for monitoring pancreatic beta cell mass or morphology |
NO20061645A NO336658B1 (en) | 2003-09-17 | 2006-04-11 | Preparation for visualizing pancreas and method for visualizing a mammalian pancreas by administering the preparation |
HK06113846.3A HK1094312A1 (en) | 2003-09-17 | 2006-12-15 | Mechanism-based targeted pancreatic beta cell imaging |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50368303P | 2003-09-17 | 2003-09-17 | |
US60/503,683 | 2003-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005027981A1 true WO2005027981A1 (en) | 2005-03-31 |
Family
ID=34375381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/030374 WO2005027981A1 (en) | 2003-09-17 | 2004-09-16 | Mechanism-based targeted pancreatic beta cell imaging and therapy |
Country Status (16)
Country | Link |
---|---|
US (2) | US7611693B2 (en) |
EP (2) | EP1675625B1 (en) |
JP (3) | JP5395327B2 (en) |
KR (2) | KR101152729B1 (en) |
CN (1) | CN1867363B (en) |
AU (1) | AU2004273911B2 (en) |
BR (1) | BRPI0414512B8 (en) |
CA (1) | CA2539384C (en) |
DK (1) | DK1675625T3 (en) |
ES (1) | ES2403378T3 (en) |
HK (1) | HK1094312A1 (en) |
IL (1) | IL174374A (en) |
NO (1) | NO336658B1 (en) |
PL (1) | PL1675625T3 (en) |
PT (1) | PT1675625E (en) |
WO (1) | WO2005027981A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006104401A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
WO2007005283A2 (en) | 2005-06-29 | 2007-01-11 | Trustees Of Columbia University In The City Of New York | Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes |
WO2008038302A2 (en) * | 2006-09-26 | 2008-04-03 | Jegannathan Srinivas | Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger. |
WO2008038304A2 (en) * | 2006-09-26 | 2008-04-03 | Jegannathan Srinivas | Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1867363B (en) * | 2003-09-17 | 2010-05-12 | 得克萨斯大学体系董事会 | Mechanism-based targeted pancreatic beta cell imaging and therapy |
AU2008353360A1 (en) | 2008-03-24 | 2009-10-01 | The Board Of Regents Of The University Of Texas System | Image-guided therapy of myocardial disease: composition, manufacturing and applications |
US20120177571A1 (en) * | 2009-07-31 | 2012-07-12 | Riken | Pancreatic endocrine cell indicating agent and utilization of same |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2951135A1 (en) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | SULFONYL UREAS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE |
JPS57102820A (en) | 1980-12-19 | 1982-06-26 | Nippon Mejifuijitsukusu Kk | Agent for radiodiagnosis |
JPS5944329A (en) | 1982-09-07 | 1984-03-12 | Nippon Mejifuijitsukusu Kk | Novel radioactive diagnostic agent |
JPS59193833A (en) | 1983-04-19 | 1984-11-02 | Nippon Mejifuijitsukusu Kk | Novel radioactive diagnostic containing bifunctional ligand compound |
US4732864A (en) | 1983-10-06 | 1988-03-22 | E. I. Du Pont De Nemours And Company | Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules |
JPS6354321A (en) | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | Blood sugar lowering agent |
JPH01186899A (en) | 1988-01-18 | 1989-07-26 | Nippon Mejifuijitsukusu Kk | Tc-99m mononuclear complex having membrane permeability |
MY106120A (en) * | 1988-12-05 | 1995-03-31 | Novartis Ag | Peptide derivatives. |
US5094837A (en) | 1990-01-22 | 1992-03-10 | Wayne State University | Method for use of magnetic resonance imaging to image pancreas using secretin |
US4994258A (en) | 1990-03-05 | 1991-02-19 | Merck & Co., Inc. | Gamma emitting, CCK-A antagonists for pancreatic imaging |
FR2661187B1 (en) | 1990-04-20 | 1994-08-05 | Inst Nat Sante Rech Med | PROTEIN ASSOCIATED WITH ACUTE PANCREATITIS. MEANS FOR THE DIAGNOSIS OF ACUTE PANCREATITIS. |
JPH05186372A (en) | 1991-07-18 | 1993-07-27 | Green Cross Corp:The | Fat emulsion and contrast medium for mri diagnosis |
US5463116A (en) | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
JP3465247B2 (en) | 1992-12-28 | 2003-11-10 | アベンティス ファーマ株式会社 | Prevention and treatment of arteriosclerosis |
US5656600A (en) * | 1993-03-25 | 1997-08-12 | Corvas International, Inc. | α-ketoamide derivatives as inhibitors of thrombosis |
US5879657A (en) * | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
DE4336159A1 (en) | 1993-10-22 | 1995-04-27 | Kurt Heinz Prof Dr Bauer | Highly effective forms of preparation of sulfonylureas that release the active ingredient quickly or in a controlled manner and processes for their preparation |
US5763200A (en) * | 1995-05-12 | 1998-06-09 | Biomeasure, Incorporated | Inhibition of amylin release |
EP0968001B1 (en) | 1997-02-03 | 2003-11-05 | Mallinckrodt Inc. | Method for the detection and localization of malignant human pancreatic tumours |
WO2000023603A2 (en) | 1998-10-21 | 2000-04-27 | Arch Development Corporation | Methods of treatment of type 2 diabetes |
US6358491B1 (en) | 1999-08-27 | 2002-03-19 | Berlex Laboratories, Inc. | Somatostatin analogs |
KR20020063282A (en) * | 1999-12-28 | 2002-08-01 | 아지노모토 가부시키가이샤 | Oral preparations for diabetes |
RU2281764C2 (en) * | 2000-03-17 | 2006-08-20 | Адзиномото Ко., Инк. | Medicinal agents for treatment of complications associated with diabetes mellitus and neuropathy and their using |
US20030032021A1 (en) | 2000-08-21 | 2003-02-13 | Curtis Rory A. J. | 44589, a novel human ABC transporter family member and uses thereof |
AU2002338572A1 (en) | 2001-04-13 | 2002-11-11 | Millennium Pharmaceuticals, Inc. | 66784, a novel human potassium channel and uses therefor |
CN1867363B (en) * | 2003-09-17 | 2010-05-12 | 得克萨斯大学体系董事会 | Mechanism-based targeted pancreatic beta cell imaging and therapy |
-
2004
- 2004-09-16 CN CN2004800300890A patent/CN1867363B/en active Active
- 2004-09-16 KR KR1020067005445A patent/KR101152729B1/en active IP Right Grant
- 2004-09-16 DK DK04788800.3T patent/DK1675625T3/en active
- 2004-09-16 US US10/942,615 patent/US7611693B2/en active Active
- 2004-09-16 PL PL04788800T patent/PL1675625T3/en unknown
- 2004-09-16 AU AU2004273911A patent/AU2004273911B2/en active Active
- 2004-09-16 ES ES04788800T patent/ES2403378T3/en active Active
- 2004-09-16 KR KR1020117021985A patent/KR20110119813A/en not_active Application Discontinuation
- 2004-09-16 BR BRPI0414512A patent/BRPI0414512B8/en active IP Right Grant
- 2004-09-16 JP JP2006527025A patent/JP5395327B2/en active Active
- 2004-09-16 EP EP04788800A patent/EP1675625B1/en active Active
- 2004-09-16 PT PT47888003T patent/PT1675625E/en unknown
- 2004-09-16 EP EP11188976A patent/EP2474328A3/en not_active Withdrawn
- 2004-09-16 WO PCT/US2004/030374 patent/WO2005027981A1/en active Application Filing
- 2004-09-16 CA CA2539384A patent/CA2539384C/en active Active
-
2006
- 2006-03-16 IL IL174374A patent/IL174374A/en active IP Right Grant
- 2006-04-11 NO NO20061645A patent/NO336658B1/en unknown
- 2006-12-15 HK HK06113846.3A patent/HK1094312A1/en unknown
-
2009
- 2009-11-02 US US12/610,857 patent/US20100278731A1/en not_active Abandoned
-
2010
- 2010-12-03 JP JP2010270880A patent/JP2011052016A/en active Pending
-
2014
- 2014-12-17 JP JP2014254707A patent/JP2015078223A/en active Pending
Non-Patent Citations (2)
Title |
---|
CHEN A. ET AL: "Antioxidant activity of a Schiff Base of pyridoxal aminoguanidine.", FREE RADICAL BIOLOGY & MEDICINE, vol. 35, no. 11, pages 1392 - 1403, XP002983335 * |
KALRA ET AL., JOURNAL OF CONTPUTER ASSISTED TOMOGRAPHY, vol. 26, pages 661 - 675 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006104401A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
WO2007005283A2 (en) | 2005-06-29 | 2007-01-11 | Trustees Of Columbia University In The City Of New York | Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes |
EP1907017A2 (en) * | 2005-06-29 | 2008-04-09 | The Trustees of Columbia University in the City of New York | Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes |
EP1907017A4 (en) * | 2005-06-29 | 2011-05-04 | Univ Columbia | Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes |
AU2006266229B2 (en) * | 2005-06-29 | 2013-02-21 | The Trustees Of Columbia University In The City Of New York | Use of DTBZ for imaging endocrine pancreas and beta cell mass in type 1 diabetes |
EP2698170A1 (en) * | 2005-06-29 | 2014-02-19 | The Trustees of Columbia University in the City of New York | Use of DTBZ for imaging endocrine pancreas and beta cell mass in type 1 diabetes |
WO2008038302A2 (en) * | 2006-09-26 | 2008-04-03 | Jegannathan Srinivas | Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger. |
WO2008038304A2 (en) * | 2006-09-26 | 2008-04-03 | Jegannathan Srinivas | Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. |
WO2008038304A3 (en) * | 2006-09-26 | 2008-05-22 | Jegannathan Srinivas | Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. |
WO2008038302A3 (en) * | 2006-09-26 | 2008-05-29 | Jegannathan Srinivas | Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger. |
Also Published As
Publication number | Publication date |
---|---|
KR101152729B1 (en) | 2012-06-15 |
JP2007505915A (en) | 2007-03-15 |
PT1675625E (en) | 2013-05-23 |
DK1675625T3 (en) | 2013-05-13 |
KR20110119813A (en) | 2011-11-02 |
EP2474328A2 (en) | 2012-07-11 |
JP5395327B2 (en) | 2014-01-22 |
BRPI0414512A (en) | 2006-11-07 |
CA2539384A1 (en) | 2005-03-31 |
EP1675625A4 (en) | 2009-07-15 |
AU2004273911A1 (en) | 2005-03-31 |
IL174374A0 (en) | 2006-08-01 |
CN1867363B (en) | 2010-05-12 |
PL1675625T3 (en) | 2013-08-30 |
CN1867363A (en) | 2006-11-22 |
BRPI0414512B8 (en) | 2021-05-25 |
US20100278731A1 (en) | 2010-11-04 |
EP1675625B1 (en) | 2013-02-20 |
EP2474328A3 (en) | 2012-07-18 |
US20050100506A1 (en) | 2005-05-12 |
EP1675625A1 (en) | 2006-07-05 |
ES2403378T3 (en) | 2013-05-17 |
AU2004273911B2 (en) | 2010-04-15 |
IL174374A (en) | 2011-12-29 |
JP2015078223A (en) | 2015-04-23 |
KR20060104984A (en) | 2006-10-09 |
BRPI0414512B1 (en) | 2020-11-17 |
HK1094312A1 (en) | 2007-03-30 |
US7611693B2 (en) | 2009-11-03 |
CA2539384C (en) | 2012-08-28 |
JP2011052016A (en) | 2011-03-17 |
NO336658B1 (en) | 2015-10-12 |
NO20061645L (en) | 2006-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015078223A (en) | MECHANISM-BASED TARGETED PANCREATIC β CELL IMAGING AND THERAPY | |
Yu et al. | BMS-747 158-02: a novel PET myocardial perfusion imaging agent | |
DE69819478T2 (en) | Methods for the detection and localization of malignant human pancreatic tumors | |
KR101639599B1 (en) | Peptide thiourea derivatives, their radioisotope labeled compounds and pharmaceutical composition for treatment or diagnosis of prostate cancer comprising the same as an active ingredient | |
US20190282715A1 (en) | Formulations for radiotherapy and diagnostic imaging | |
WO2020065045A1 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers | |
Seregni et al. | Treatment with tandem [^ sup 90^ Y] DOTA-TATE an [^ sup 177^ Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results | |
BRPI0621580A2 (en) | compositions and methods for cell imaging and therapy | |
JPH0772144B2 (en) | Radioactive diagnostic agent containing antibacterial agent | |
DE69230287T2 (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR DETECTING AND LOCALIZING TISSUE WITH NEUROKININ-1 RECEPTORS | |
EP1181936A1 (en) | Synthesis, biological and preclinical evaluation of (D-Phe6,Leu-NHEt13,des-Met14)bombesin(6-14) analogs modified with 1,4,8,11-tetraazaundecane derivatives and labeled with technetium-99m for application in oncology | |
EP3011976A1 (en) | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents | |
DE60014375T2 (en) | TRANSITION METAL COMPLEXES OF THE VII SUB-GROUP WITH MULTIDENTATE AMINOPOLYCARBOXYLATE LIGANDS AND A KIT FOR THEIR PREPARATION | |
US4952393A (en) | Organ infarct imaging with technetium labelled glucarate | |
IL302033A (en) | Therapeutic radiolabelled conjugates and their use in therapy | |
CN115484946A (en) | Compositions, kits and methods for diagnosing and treating prostate cancer | |
RU2788581C2 (en) | Compositions for radiotherapy and diagnostic imaging | |
JPH1059990A (en) | Radioactively marked uridine derivative and medicine containing the same | |
Sewatkar et al. | Comparison of 99mTc-Labelled Hepatobiliary Agents—99mTc-Pyridoxylidene Glutamate (99mTc-PG) and 99mTc-Sn-Lidocaine Iminodiacetic Acid (99mTc-Sn-LIDA) | |
CA3037835A1 (en) | Mibg analogs and uses thereof | |
Baranowska-Kortylewicz | Zbigniew P. Kortylewicz1| Don W. Coulter2| Guang Han3| Janina Baranowska-Kortylewicz4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480030089.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 174374 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2539384 Country of ref document: CA Ref document number: 1020067005445 Country of ref document: KR Ref document number: 2006527025 Country of ref document: JP Ref document number: 948/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004273911 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004788800 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004273911 Country of ref document: AU Date of ref document: 20040916 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004273911 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004788800 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067005445 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0414512 Country of ref document: BR |